Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A drug, an endothelin receptor antagonist used to treat pulmonary hypertension.

Etymologies

Sorry, no etymologies found.

Examples

  • Due to competitive concerns with Myogen's ambrisentan, which is expected to enter the market in 2007, timing is of the essence for Encysive.

    Encysive Shares Clouded By Uncertainty

  • Gilead has a medicine called ambrisentan for the same lung disease in the final stage of human testing generally required for regulatory approval.

    Gilead to Buy Arresto Biosciences for $225 Million to Obtain Lung Medicine - Bloomberg

  • Data on ambrisentan, however, has been very promising; many analysts think the drug can take on Actelion's similar Tracleer.

    Gilead's Big Shift

  • Myogen's lead drug, ambrisentan, is a treatment for a rare disease called pulmonary arterial hypertension, PAH, a blood pressure disorder of the lungs that makes it extremely difficult for patients to breathe.

    Gilead's Big Shift

  • GlaxoSmithKline, which markets Flolan, the current standard-of-care treatment, obtained non-U.S. marketing rights for Myogen's ambrisentan last March in exchange for U.S. rights for Flolan.

    Gilead's Big Shift

  • Myogen's lead drug candidate is ambrisentan, a new type of treatment for pulmonary arterial hypertension, a blood pressure disorder of the lungs.

    Buyouts Lift Biotechs

  • Understanding the function of the lung could help in developing other drugs that might fit in with Cayston and ambrisentan.

    Gilead's Big Shift

  • Shares of Myogen fell 10% as investors were disappointed with a recently announced deal with British drug giant GlaxoSmithKline for experimental drug ambrisentan, a treatment for pulmonary arterial hypertension.

    Tysabri News Lifts Drug Stocks

  • Separately, Myogen said it forged an alliance with British drug giant GlaxoSmithKline for experimental drug ambrisentan, a treatment for pulmonary arterial hypertension.

    Eye On Stocks For Tuesday, March 7, 2006Eye On Stocks For Tuesday, March 7

  • "We are maintaining our 'hold' rating, as we expect near-term weakness driven by visibility on Myogen's ambrisentan and a potentially slow launch due to the wide acceptance of Pfizer's Revatio," the firm said.

    Eye On Stocks For Friday, March 24, 2006 Eye On Stocks For Friday, March 24

Wordnik is becoming a not-for-profit! Read our announcement here.

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.